Meta-analysis confirms a single dose of THC induces psychotic, negative, and other psychiatric symptoms with large effect sizes | Research

The takeaway

A meta-analysis of 15 controlled studies found that a single administration of THC significantly increased psychotic symptoms (effect size 0.91), negative symptoms (0.78), and total psychiatric symptoms (1.10) in healthy people, while CBD showed no consistent moderating effect.

Psychiatrists, cannabis researchers, and policy makers evaluating THC-related psychiatric risks.

THC effect size for psychotic symptoms: 0.91 (large)

What the researchers found

THC produced large effect sizes for total symptoms (SMC 1.10), positive/psychotic symptoms (SMC 0.91), and negative symptoms (SMC 0.78) compared to placebo. Of four studies examining CBD's ability to moderate THC effects, only one found a significant reduction.

Why it matters

This is the most comprehensive meta-analysis of controlled THC administration studies, providing definitive effect size estimates for THC-induced psychiatric symptoms and finding no consistent evidence that CBD protects against these effects.

The numbers in context

Total symptoms: SMC 1.10 (95% CI 0.92-1.28, p<0.0001) in 196 participants. Positive symptoms: SMC 0.91 (95% CI 0.68-1.14, p<0.0001) in 324 participants. Negative symptoms: SMC 0.78 (95% CI 0.59-0.97, p<0.0001) in 267 participants.

How the study worked

Systematic review and meta-analysis of within-person crossover studies administering THC (IV, oral, or nasal) and placebo to healthy participants, with psychiatric symptoms measured by BPRS or PANSS. 15 THC studies and 4 CBD+THC studies were included.

What this study cannot tell us

Most studies used intravenous THC, which does not replicate typical cannabis use. Participants were healthy volunteers, not people at high risk for psychosis. Studies of CBD moderation were few (only 4) and heterogeneous.

How to read the evidence

Strong: systematic review and meta-analysis of controlled within-person crossover studies, published in The Lancet Psychiatry.

When this study was published

Published in 2020 in The Lancet Psychiatry.

The bigger picture

The large effect sizes across all symptom domains confirm that THC is a potent psychotomimetic, while the lack of consistent CBD protection challenges the assumption that balanced THC:CBD products are inherently safer for psychiatric risk.

Questions still open

Why did CBD not consistently moderate THC effects? Would higher CBD doses be needed? Do these acute laboratory effects translate to real-world psychiatric risk from cannabis use?

Common questions

How significant are these effect sizes?

All effect sizes were classified as large (above 0.8). For context, this means THC's effect on psychiatric symptoms is substantial and clinically meaningful, not a subtle statistical finding.

Does CBD protect against THC-induced psychosis?

Based on the four available studies, there was no consistent evidence that CBD moderates THC-induced psychiatric symptoms. Only one of four studies found a significant protective effect.

Read the original research

Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.

The lancet. Psychiatry, 7(4), 344-353

View on PubMed ↗Publisher’s paper ↗

Citation

Hindley, Guy; Beck, Katherine; Borgan, Faith; Ginestet, Cedric E; McCutcheon, Robert; Kleinloog, Daniel; Ganesh, Suhas; Radhakrishnan, Rajiv; D'Souza, Deepak Cyril; Howes, Oliver D. (2020). Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.. The lancet. Psychiatry, 7(4), 344-353. https://doi.org/10.1016/S2215-0366(20)30074-2